ADAMTS13, recombinant (Pending FDA Approval)

Brand and Other Names:
Sections

Dosing & Uses

AdultPediatric

See Pediatric Dosing & Uses

Congenital Thrombotic Thrombocytopenic Purpura

Pending FDA approval for enzyme replacement therapy of congenital thrombotic thrombocytopenic purpura (cTTP), an ADAMTS13 gene deficiency disorder

Next:

Pharmacology

Mechanism of Action

Congenital thrombotic thrombocytopenic purpura (cTTP), is an ADAM metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13) gene deficiency disorder

ADAMTS13 enzyme splices von Willebrand factor to regulate its interaction with platelets; this action is involved in platelet adhesion to form temporary clots at the site of an injury

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.